数字农科院2.0

EGCG and DOX dual-drug-loaded enzyme-responsive nanovesicles boost mitochondrial-mediated ICD for improved immunotherapy

文献类型： 外文期刊

作者： Mengxue Zhou;Ying Wang;Hongchun Cui;Huan Geng;Lifo Ruan;Yanni Zhao;Chuang Zhou;Weidong Dai;Jun Chen;Jizhong Yu;Haipeng Lv;Zhi Lin

作者机构：

关键词： cancer immunotherapy;EGCG;mitochondria-targeted;MMP-2 sensitive nanovesicles;tumor fibrosis

期刊名称： Frontiers in Pharmacology

ISSN： 1663-9812

年卷期： 2025 年 16 卷

页码：

收录情况： SCIE（2025版）

摘要： Enhancing cancer immunotherapy using methods that induce immunogenic cell death (ICD) can significantly improve its effectiveness and profoundly influence its role as a highly efficient cancer treatment strategy. However, the limited penetration of cytotoxic T cells into tumors, owing to dense tumor fibrosis, remains a significant barrier to immunotherapy. A tumor microenvironment-sensitive intelligent dual-drug delivery system was developed to simultaneously deliver epigallocatechin-3-gallate (EGCG) and doxorubicin (DOX) to mitochondria. EGCG enhanced the mitochondria-targeted action of DOX and increased damage to the mitochondrial electron transport chain which facilitated capturing electrons in the mitochondrial matrix of DOX. Subsequently, DOX molecules form a semiquinone intermediate and electrons are transferred to oxygen to generate reactive oxygen species (ROS) that induce mitochondrial apoptosis. These results indicate that EGCG amplifies the combined effects of chemo/chemodynamic therapy of DOX, demonstrating a pronounced synergistic ICD effect that recruits CD8+ T cells to the tumor microenvironment (TME). In addition, EGCG promotes T-cell infiltration into tumor tissues by inhibiting the transforming growth factor-β signaling pathway, thereby significantly enhancing antitumor efficacy. This study advances the efficacy of immunotherapy through bidirectional synergy, which not only enhances intrinsic tumor immunogenicity but also overcomes the extrinsic physical barriers of tumors, providing a new direction for the development of broadly applicable immunotherapies.

分类号：

  • 相关文献

[1]Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice. Liu, Guang-yao,Liu, Ming-yuan,Wang, Xue-lin,Li, Yang,Li, Zhi-jie,Jia, Qiu-ying,Li, Ya-gang,Zhang, Meng-meng,Liu, Ming-yuan.

[2]Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L. Liu, Guang-yao,Li, Qing-lin,Liu, Ming-yuan,Li, Yang,Li, Zhi-jie,Jin, Yan,Zhu, Yu-hui,Wang, Yue-hui,Li, Ya-gang,Liu, Ming-yuan. 2015

[3]Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas. Zhao, Dong-xu,Zhao, Kun-chi,Liu, Ming-yuan,Li, Yang,Li, Zhi-jie,Li, Ya-gang,Zhang, Meng-meng,Zhang, Yang,Zhang, Xiao-na,Yu, Xiao-wei,Liu, Ming-yuan.

[4]表没食子儿茶素没食子酸酯参与老年小鼠心脏SERCA2a的调控及其机制. 全珺珺,潘博,贾忠莉,刘玲娟,田杰. 2017

[5]茶与健康研究的前景与挑战. 陈宗懋. 2019

[6]茶叶中EGCG对小鼠抗凝血作用实验研究. 王贤波,成浩,赵芸,黄海涛. 2011

[7]EGCG甲基化衍生物的清除DPPH自由基活性和总抗氧化活性. 吕海鹏,林智,谭俊峰,郭丽,张悦,费旭元. 2011

[8]茶与健康专题(六)茶的杀菌和抗病毒功效. 陈宗懋. 2009

[9]传统SMB、Varicol和Partial-discard工艺分离纯化ECG和EGCG的比较研究. 黄永东,江和源,江用文,张建勇,王斌,白艳,文志浩,王伟伟. 2011

[10]茶与健康专题(八)茶叶抗癌的效果:过去、现在和将来. 陈宗懋. 2009

[11]介孔氧化硅SBA-15作为高效吸附剂用于绿茶提取物中EGCG的选择性吸附研究. 马桂岑,章剑扬,陈利燕,张颖彬,刘新. 2014

[12]乙酰化EGCG的制备研究. 刘晓辉,江和源,张建勇,袁新跃,崔宏春. 2009

[13]SMB、Varicol和Partial-discard工艺分离茶多酚. 黄永东,江和源,江用文,王斌. 2010

[14]EGCG乙酰化衍生物清除自由基活性的构效分析. 王伟伟,苏威,江和源,张建勇,施莉婷. 2017

[15]EGCG纳米载体制备技术及其对EGCG活性影响的研究进展. 祁洁,徐颖磊,梁文怡,费朵,乌昕儿,金建昌,杜琪珍,许勇泉,高颖. 2017

[16]PBD和RSM联用优化聚酯型儿茶素A化学合成技术参数. 张建勇,陈琳,崔宏春,王伟伟,薛金金,熊春华,江和源. 2020

[17]茶叶中EGCG的制备化分离新技术. 杜琪珍,沈星荣,蒋迎. 2000

[18]儿茶素生物医用纳米材料研究进展. 俞蓉欣,郑芹芹,陈红平,张劲松,张相春. 2022

[19]EGCG和异鼠李素的细胞抗氧化协同作用. 潘俊坤,焦中高,张强. 2023

[20]The Effects And Mechanisms Of E.pigallocatechin-3-Gallate On Reversing Multidrug R esistance In Cancer. Sun, Lingli,Zhang, Wenjuan,Lai, Xingfei,Sun, Shili,Zhang, Wenji,Xiang, Limin,Li, Qiuhua. 2019

作者其他论文 更多>>